Platelets as potential immunomodulators: Is there a role for platelet toll-like receptors?

Current Immunology Reviews

Volumn 3, Issue 2, 2007, Pages 109-115

  Cognasse, Fabrice ^a   Semple, John W ^b   Garraud, Olivier ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adaptative and innate immunity; CD40 CD40L; Platelets; TLRs

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CHAPERONE; CHEMOKINE; CYTOKINE; FC RECEPTOR; HEAT SHOCK PROTEIN 20; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; LIGAND; PADGEM PROTEIN; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; CELL DAMAGE; CELL INTERACTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; HEMOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE; MEGAKARYOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA;

EID: 34249278466     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339507780655522     Document Type: Review

References (112)

1. Bird AP. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res 1980; 8: 1499-504.
2. Wyllie DH, Kiss-Toth E, Visintin A, et al. Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses. J Immumol 2000; 165: 7125-32.
3. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000; 165: 5392-6.
4. Hajjar AM, O'Mahony DS, Ozinsky A, et al. Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 2001; 166: 15-9.
5. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
6. Imler JL, Hoffmann JA. Toll receptors in innate immunity. Trends Cell Biol 2001; 11: 304-11.
7. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-95.
8. Spitzer JH, Visintin A, Mazzoni A, Kennedy MN, Segal DM. Toll-like receptor 1 inhibits Toll-like receptor 4 signaling in endothelial cells. Eur J Immunol 2002; 32: 1182-7.
9. Underhill DM. Toll-like receptors and microbes take aim at each other. Curr Opin Immunol 2004; 16: 483-7.
10. Underhill DM, Ozinsky A, Hajjar AM, et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999; 401: 811-5.
11. Underhill DM, Ozinsky A, Smith KD, Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A 1999; 96: 14459-63.
12. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 2005; 560: 11-8.
13. Lauw FN, Caffrey DR, Golenbock DT. Of mice and man: TLR11 (finally) finds profilin. Trends Immunol 2005; 26: 509-11.
14. Medzhitov R, Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91: 295-8.
15. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7.
16. Poltorak A, He X, Smimova I, et al. Defective LPS signaling in C3H/ HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-8.
17. Qureshi ST, Lariviere L, Leveque G, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Thr4). J Exp Med 1999; 189: 615-25.
18. Qureshi ST, Medzhitov R. Toll-like receptors and their role in experimental models of microbial infection. Genes Immun 2003; 4: 87-94.
19. Shirota H, Sano K, Hirasawa N, et al. Novel roles of CpG oligode-oxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 2001; 167: 66-74.
20. Shirota H, Sano K, Hirasawa N, et al. B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating EL-12. J Immunol 2002; 169: 787-94.
21. da Silva Correia J, Soldau Y, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001; 276: 21129-35.
22. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect 2004; 6: 1382-7.
23. Finberg RW, Wang JP, Kurt-Jones EA. Toll like receptors and viruses. Rev Med Virol 2007; 17: 35-43.
24. Ban E, Dupre L, Hermann E, et al. CpG motifs induce Langerhans cell migration in vivo. Int Immunol 2000; 12: 737-45.
25. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777-82.
26. Ogata H, Su I, Miyake K, et al. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med 2000; 192: 23-9.
27. Warren HS. Toll-like receptors. Crit Care Med 2005; 33: S457-9.
28. Warren TL, Bhatia SK, Acosta AM, et al. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class 1-restricted T cells. J Immunol 2000; 165: 6244-51.
29. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-7.
30. Viglianti GA, Lau CM, Hanley TM, et al. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003; 19: 837-47.
31. Rui L, Vinuesa CG, Blasioli J, Goodnow CC. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat Immunol 2003; 4: 594-600.
32. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Ent J Immunol 2001; 31: 3388-93.
33. Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 2000; 30: 3591-7.
34. Cognasse F, Hamzeh H, Chavarin P, et al. Evidence of Toll Like Receptor molecules on human platelets. Immunol Cell Biol 2005; 83: 196-8.
35. Shiraki R, Inoue N, Kawasaki S, et al. Expression of Toll-like receptors on human platelets. Thromb Res 2004; 113: 379-85.
36. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
37. Steinhubl SR. Platelets as mediators of inflammation. Hematol Oncol Clin North Am 2007; 21: 115-21.
38. Ahmad-Nejad P, Hacker H, Rutz M, et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32: 1958-68.
39. Chu W, Gong X, Li Z, et al. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell 2000; 103: 909-18.
40. Apelseth TO, Hervig TA, Wentzel-Larsen T, Bruserud O. Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006; 46: 800-10.
41. Cardigan R, Sutherland J, Wadhwa M, Dilger P, Thorpe R. The influence of platelet additive solutions on cytokine levels and complement activation in platelet concentrates during storage. Vox Sang 2003; 84: 28-35.
42. Cognasse F, Boussoulade F, Chavarin P, et al. Release of potential immunomodulatory factors during platelet storage. Transfusion 2006; 46: 1184-9.
43. Vetlesen A, Mirlashari MR, Ezligini F, Kjeldsen-Kragh J. Evaluation of platelet activation and cytokine release during storage of platelet concentrates processed from huffy coats either manually or by the automated OrbiSac system. Transfusion 2007; 47: 126-32.
44. Hagihara M, Higuchi A, Tamura N, et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol 2004; 172: 5297-303.
45. Mason PJ, Chakrabarti S, Albers AA, et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 2005; 96: 1365-9.
46. Otterdal K, Pedersen TM, Solum NO. Release of soluble CD40 ligand after platelet activation; Studies on the solubilization phase. Thromb Res 2004; 114: 167-77.
47. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.
48. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041-8.
49. Armitage RJ, Macduff BM, Spriggs MK, Fanslow WC. Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. J Immunol 1993; 150: 3671-80.
50. Armitage RJ, Maliszewski CR, Alderson MR, et al. CD40L: a multi-functional ligand. Semin Immunol 1993; 5: 401-12.
51. Cognasse F, Chavarin P, Acquart S, et al. Differential downstream effects of CD40 ligation mediated by membrane or soluble CD40L and agonistic Ab: a study on purifed human B cells. Int J Immunopathol Pharmacol 2005; 18: 65-74.
52. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
53. Weller S, Faili A, Garcia C, et al. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A 2001; 98: 1166-70.
54. Shimizu N, Haraguchi Y, Takeuchi Y, et al. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Virology 1999; 259: 324-33.
55. Underhill DM. Toll-like receptors: networking for success. Eur J Immunol 2003; 33: 1767-75.
56. Brown V, Brown RA, Ozinsky A, Hesselberth JR, Fields S. Binding specificity of Toll-like receptor cytoplasmic domains. Eur J Immunol 2006; 36: 742-53.
57. Cognasse F, Garraud O. Human platelets exhibit infectious-pathogen binding ligands and participate to inflammation (and more?). Exp Hematol 2005; 33: 1081-2.
58. Aslam R, Speck ER, Kim M, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006; 107: 637-41.
59. Andonegui G, Kerfoot SM, McNagny K, et al. Platelets express functional Toll-like receptor-4. Blood 2005; 106: 2417-23.
60. Ward JR, Bingle L, Judge HM, et al. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost 2005; 94: 831-8.
61. Jayachandran M, Brunn GJ, Karnicki K, et al. In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J Appl Physiol 2007; 102: 429-33.
62. Stahl AL, Svensson M, Morgelin M, et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets via TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 2006.
63. Malhotra R, Priest R, Foster MR, Bird MI. P-selectin binds to bacterial lipopolysaccharide. Eur J Immunol 1998; 28: 983-8.
64. Kanno Y, Matsuno H. The possibility of novel antiplatelet peptides: the physiological effects of low molecular weight HSPs on platelets. Curr Pharm Des 2006; 12: 887-92.
65. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004; 76: 514-9.
66. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-61.
67. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004; 93: 97-108.
68. Whittall T, Wang Y, Younson J, et al. Interaction between the CCR5 chemokine receptors and microbial HSP70. Eur J Immunol 2006; 36: 2304-14.
69. Lazarevic V, Myers AJ, Scanga CA, Flynn JL. CD40, but not CD40L, is required for the optimal priming of T cells and control of aerosol M. tuberculosis infection. Immunity 2003; 19: 823-35.
70. Theriault JR, Adachi H, Calderwood SK. Role of scavenger receptors in the binding and internalization of heat shock protein 70. J Immunol 2006; 177: 8604-11.
71. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1626-31.
72. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-84.
73. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-50.
74. Elovitz MA, Wang Z, Chien EK, Rychlik DF, Phillippe M. A new model for inflammation-induced preterm birth: the role of platelet-activating factor and Toll-like receptor-4. Am J Pathol 2003; 163: 2103-11.
75. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22: 913-22.
76. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30: S294-301.
77. Mannaioni PF, Di Bello MG, Masini E. Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res 1997; 46: 4-18.
78. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
79. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-54.
80. Czapiga M, Kirk AD, Lekstrom-Himes J. Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. Exp Hematol 2004; 32: 135-9.
81. Elzey BD, Tian J, Jensen RJ, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003; 19: 9-19.
82. Hamzeh-Cognasse H, Cognasse F, Delezay O, Chavarin P, Garraud O. Inhibition of human dendritic cell activation by membrane-bound platelets. submitted.
83. Crist SA, Elzey BD, Ludwig AT, et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Exp Hematol 2004; 32: 1073-81.
84. Elzey BD, Grant JF, Sinn HW, et al. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukoc Biol 2005; 78: 80-4.
85. Solanilla A, Pasquet JM, Viallard JF, et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005; 105: 215-8.
86. Xu H, Zhang X, Mannon RB, Kirk AD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest 2006; 116: 769-74.
87. Cognasse F, Hamzeh H, Chavarin P, et al. Human platelets are capable of stimulating peripheral blood B lymphocytes and altering the production of immunoglobulins. submitted.
88. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006; 108: 2455-62.
89. Cognasse F, Hamzeh-Cognasse H, Lafarge S, et al. Toll-like receptor 4 ligand stimulates immunomodulatory factor release by human platelets. submitted.
90. Cognasse F, Lafarge S, Chavarin P, Acquart S, Garraud O. Lipopolysaccharide induces sCD40L release through human platelets TLR4, but not TLR2 and TLR9. Intensive Care Med 2007; 33: 382-4.
91. Damas JK, Jensenius M, Ueland T, et al. Increased levels of soluble CD40L in African tick bite fever: possible involvement of TLRs in the pathogenic interaction between Rickettsia africae, endothelial cells, and platelets. J Immunol 2006; 177: 2699-706.
92. Siboo IR, Chambers HF, Sullam PM. Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets. Infect Immun 2005; 73: 2273-80.
93. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood 2002; 99: 4021-9.
94. Kupferwasser LI, Yeaman MR, Shapiro SM, Nast CC, Bayer AS. In vitro susceptibility to thrombin-induced platelet microbicidal protein is associated with reduced disease progression and complication rates in experimental Staphylococcus aureus endocarditis: microbiological, histopathologic, and echocardiographic analyses. Circulation 2002; 105: 746-52.
95. Mercier RC, Rybak MJ, Bayer AS, Yeaman MR. Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis. Infect Immun 2000; 68: 4699-705.
96. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70: 6524-33.
97. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25: 489-95.
98. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol 2005; 238: 1-9.
99. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 2005; 25: 2428-34.
100. Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis 1997; 25: 951-68; quiz 69-70.
101. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13: 463-9.
102. Lee WJ, Sheu WH, Chen YT, et al. Circulating CD40 ligand is elevated only in patients with more advanced symptomatic peripheral arterial diseases. Thromb Res 2005.
103. Shanwell A, Falker C, Gulliksson H. Storage of platelets in additive solutions: the effects of magnesium and potassium on the release of RANTES, beta-thromboglobulin, platelet factor 4 and interleukin-7, during storage. Vox Sang 2003; 85: 206-12.
104. Wadhwa M, Krailadsiri P, Dilger P, et al. Cytokine levels as performance indicators for white blood cell reduction of platelet concentrates. Vox Sang 2002; 83: 125-36.
105. Boehlen F, Clemetson KJ. Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice? Transfus Med 2001; 11: 403-17.
106. Clemetson KJ, Clemetson JM, Proudfoot AE, et al. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96: 4046-54.
107. Semple JW, Aslam R, Kim M, Speck ER, Freedman J. Platelet-bound lipopolysaccharide enhances Fc Receptor mediated phagocytose of IgG opsonized platelets. Blood 2007: in press.
108. Akira S. Toll-like receptor signaling. J Biol Chem 2003; 278(40): 38105-8.
109. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
110. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
111. Kaisho T, Akira S. Toll-like receptors and their signaling mechanism in innate immunity. Acta Odontol Scand 2001; 59: 124-30.
112. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002; 1589: 1-13.